Literature DB >> 27612997

Hyperoxaluria Requires TNF Receptors to Initiate Crystal Adhesion and Kidney Stone Disease.

Shrikant R Mulay1, Jonathan N Eberhard1, Jyaysi Desai1, Julian A Marschner1, Santhosh V R Kumar1, Marc Weidenbusch1, Melissa Grigorescu1, Maciej Lech1, Nuru Eltrich1, Lisa Müller2, Wolfgang Hans3, Martin Hrabě de Angelis3,4,5, Volker Vielhauer1, Bernd Hoppe6, John Asplin7, Nicolai Burzlaff2, Martin Herrmann8, Andrew Evan9, Hans-Joachim Anders10.   

Abstract

Intrarenal crystals trigger inflammation and renal cell necroptosis, processes that involve TNF receptor (TNFR) signaling. Here, we tested the hypothesis that TNFRs also have a direct role in tubular crystal deposition and progression of hyperoxaluria-related CKD. Immunohistochemical analysis revealed upregulated tubular expression of TNFR1 and TNFR2 in human and murine kidneys with calcium oxalate (CaOx) nephrocalcinosis-related CKD compared with controls. Western blot and mRNA expression analyses in mice yielded consistent data. When fed an oxalate-rich diet, wild-type mice developed progressive CKD, whereas Tnfr1-, Tnfr2-, and Tnfr1/2-deficient mice did not. Despite identical levels of hyperoxaluria, Tnfr1-, Tnfr2-, and Tnfr1/2-deficient mice also lacked the intrarenal CaOx deposition and tubular damage observed in wild-type mice. Inhibition of TNFR signaling prevented the induced expression of the crystal adhesion molecules, CD44 and annexin II, in tubular epithelial cells in vitro and in vivo, and treatment with the small molecule TNFR inhibitor R-7050 partially protected hyperoxaluric mice from nephrocalcinosis and CKD. We conclude that TNFR signaling is essential for CaOx crystal adhesion to the luminal membrane of renal tubules as a fundamental initiating mechanism of oxalate nephropathy. Furthermore, therapeutic blockade of TNFR might delay progressive forms of nephrocalcinosis in oxalate nephropathy, such as primary hyperoxaluria.
Copyright © 2017 by the American Society of Nephrology.

Entities:  

Keywords:  Chronic inflammation; Hyperoxaluria; Kidney stone; pathology

Mesh:

Substances:

Year:  2016        PMID: 27612997      PMCID: PMC5328164          DOI: 10.1681/ASN.2016040486

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  30 in total

1.  Role of tumor necrosis factor-α and interleukin-1β in anorexia induction following oral exposure to the trichothecene deoxynivalenol (vomitoxin) in the mouse.

Authors:  Wenda Wu; Haibin Zhang
Journal:  J Toxicol Sci       Date:  2014       Impact factor: 2.196

2.  Human Mincle Binds to Cholesterol Crystals and Triggers Innate Immune Responses.

Authors:  Ryoko Kiyotake; Masatsugu Oh-Hora; Eri Ishikawa; Tomofumi Miyamoto; Tatsuro Ishibashi; Sho Yamasaki
Journal:  J Biol Chem       Date:  2015-08-20       Impact factor: 5.157

Review 3.  Primary and secondary hyperoxaluria: Understanding the enigma.

Authors:  Bhavna Bhasin; Hatice Melda Ürekli; Mohamed G Atta
Journal:  World J Nephrol       Date:  2015-05-06

4.  Crystal surface adhesion explains the pathological activity of calcium oxalate hydrates in kidney stone formation.

Authors:  Xiaoxia Sheng; Michael D Ward; Jeffrey A Wesson
Journal:  J Am Soc Nephrol       Date:  2005-06-01       Impact factor: 10.121

Review 5.  Enteric hyperoxaluria: an important cause of end-stage kidney disease.

Authors:  Lama Nazzal; Sonika Puri; David S Goldfarb
Journal:  Nephrol Dial Transplant       Date:  2015-02-20       Impact factor: 5.992

6.  Annexin II is present on renal epithelial cells and binds calcium oxalate monohydrate crystals.

Authors:  Vivek Kumar; Gerard Farell; Sergio Deganello; John C Lieske
Journal:  J Am Soc Nephrol       Date:  2003-02       Impact factor: 10.121

7.  TNF-alpha receptor antagonist, R-7050, improves neurological outcomes following intracerebral hemorrhage in mice.

Authors:  Melanie D King; Cargill H Alleyne; Krishnan M Dhandapani
Journal:  Neurosci Lett       Date:  2013-03-07       Impact factor: 3.046

8.  Colony-stimulating factor-1 signaling suppresses renal crystal formation.

Authors:  Kazumi Taguchi; Atsushi Okada; Hiroshi Kitamura; Takahiro Yasui; Taku Naiki; Shuzo Hamamoto; Ryosuke Ando; Kentaro Mizuno; Noriyasu Kawai; Keiichi Tozawa; Kenichi Asano; Masato Tanaka; Ichiro Miyoshi; Kenjiro Kohri
Journal:  J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 10.121

9.  Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease.

Authors:  Shrikant R Mulay; Andrew Evan; Hans-Joachim Anders
Journal:  Nephrol Dial Transplant       Date:  2013-10-25       Impact factor: 5.992

10.  Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL/6 mice.

Authors:  Shrikant R Mulay; Jonathan N Eberhard; Victoria Pfann; Julian A Marschner; Murthy N Darisipudi; Christoph Daniel; Simone Romoli; Jyaysi Desai; Melissa Grigorescu; Santhosh V Kumar; Birgit Rathkolb; Eckhard Wolf; Martin Hrabě de Angelis; Tobias Bäuerle; Barbara Dietel; Carsten A Wagner; Kerstin Amann; Kai-Uwe Eckardt; Peter S Aronson; Hans Joachim Anders; Felix Knauf
Journal:  Am J Physiol Renal Physiol       Date:  2016-01-13
View more
  26 in total

1.  Stones: TNFRs mediate CaOx deposition in hyperoxaluria.

Authors:  Ellen F Carney
Journal:  Nat Rev Nephrol       Date:  2016-09-26       Impact factor: 28.314

2.  Development of a Kidney Calcification Inhibitor Employing Image-Based Profiling: A Proof-of-Concept Study.

Authors:  Anna Kletzmayr; Melina Bigler; Elita Montanari; Makoto Kuro-O; Hirosaka Hayashi; Mattias E Ivarsson; Jean-Christophe Leroux
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-23

3.  Protective effects of finasteride against testosterone-induced calcium oxalate crystallization and crystal-cell adhesion.

Authors:  Kanyarat Sueksakit; Visith Thongboonkerd
Journal:  J Biol Inorg Chem       Date:  2019-07-24       Impact factor: 3.358

4.  Deregulated MTOR (mechanistic target of rapamycin kinase) is responsible for autophagy defects exacerbating kidney stone development.

Authors:  Rei Unno; Tsuyoshi Kawabata; Kazumi Taguchi; Teruaki Sugino; Shuzo Hamamoto; Ryosuke Ando; Atsushi Okada; Kenjiro Kohri; Tamotsu Yoshimori; Takahiro Yasui
Journal:  Autophagy       Date:  2019-06-29       Impact factor: 16.016

Review 5.  Novel therapeutic approaches for the primary hyperoxalurias.

Authors:  Ruth Belostotsky; Yaacov Frishberg
Journal:  Pediatr Nephrol       Date:  2020-11-06       Impact factor: 3.714

6.  Inflammatory Cells in Nephrectomy Tissue from Patients without and with a History of Urinary Stone Disease.

Authors:  Pegah Dejban; Elena M Wilson; Muthuvel Jayachandran; Loren P Herrera Hernandez; Zejfa Haskic; Linda E Wellik; Sutapa Sinha; Andrew D Rule; Aleksandar Denic; Kevin Koo; Aaron M Potretzke; John C Lieske
Journal:  Clin J Am Soc Nephrol       Date:  2022-01-25       Impact factor: 8.237

7.  Relationship between the dietary inflammatory index and kidney stone prevalence.

Authors:  Nuozhou Liu; Ying Feng; Jili Li; Xue Ma; Fang Ma
Journal:  World J Urol       Date:  2022-04-09       Impact factor: 4.226

8.  miRNA-34a inhibits cell adhesion by targeting CD44 in human renal epithelial cells: implications for renal stone disease.

Authors:  Bohan Wang; Gaofei He; Gang Xu; Jiaming Wen; Xiao Yu
Journal:  Urolithiasis       Date:  2019-09-10       Impact factor: 3.436

9.  Cellular and Molecular Mechanisms of Kidney Injury in 2,8-Dihydroxyadenine Nephropathy.

Authors:  Barbara Mara Klinkhammer; Sonja Djudjaj; Uta Kunter; Runolfur Palsson; Vidar Orn Edvardsson; Thorsten Wiech; Margret Thorsteinsdottir; Sverrir Hardarson; Orestes Foresto-Neto; Shrikant R Mulay; Marcus Johannes Moeller; Wilhelm Jahnen-Dechent; Jürgen Floege; Hans-Joachim Anders; Peter Boor
Journal:  J Am Soc Nephrol       Date:  2020-02-21       Impact factor: 10.121

Review 10.  Novel Insights into Crystal-Induced Kidney Injury.

Authors:  Shrikant R Mulay; Chongxu Shi; Xiaoyuan Ma; Hans Joachim Anders
Journal:  Kidney Dis (Basel)       Date:  2018-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.